Heart transplantation immunosuppressive therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(13 intermediate revisions by the same user not shown)
Line 2: Line 2:
{{Heart transplantation}}
{{Heart transplantation}}


'''Editor(s)-in-Chief:''' [[C. Michael  Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}
'''Editor(s)-in-Chief:''' [[C. Michael  Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}{{IF}}


==Immunosuppressive Therapy==
==Overview==
===[[Cyclosporine A]]===
Post cardiac transplantation, medical therapy with [[Immunosuppressive therapy|immunosuppressive]] drugs is essential to prevent both [[Transplant rejection|acute and chronic rejection]]. [[Immunosuppressive therapy]] is given in two phases- Induction therapy and Maintenance therapy. The drugs used include different combinations of drugs like IL-2 Receptor antagonists, Anti-[[thymocyte]] [[antibodies]], [[calcineurin inhibitor]], anti-metabolite, [[glucocorticoids]], mammalian target of [[rapamycin]] [m-TOR] inhibitors, proliferation signal inhibitors and monoclonal Antibody OKT3.
====Cyclosporine Induced Hypertension====
Hypertension occurs in 60% of patients on cyclosporine. The etiology is thought to be due to vasoconstriction. There is a loss of [[circadian rhythm]] in blood pressure.  [[Verapamil]], [[cardizem]] and [[nicardipine]] increase cyclosporine concentrations.


===[[Adrenocortical steroids]]===
==Medical Therapy==


===[[Azathioprine]]===
*Immunosuppressive medical therapy is recommended in patients after undergoing cardiac transplantation.
*Pharmacologic medical therapies or Post-transplantation [[immunosuppressive]] therapy includes two stages-
** Induction- Intense therapy for the first 2-3 months to prevent [[acute graft rejection]]
** Maintenance- Throughout the life of the patient to combat both [[Acute (medicine)|acute]] and [[chronic rejection]]. <ref name="ChambersYusen2017">{{cite journal|last1=Chambers|first1=Daniel C.|last2=Yusen|first2=Roger D.|last3=Cherikh|first3=Wida S.|last4=Goldfarb|first4=Samuel B.|last5=Kucheryavaya|first5=Anna Y.|last6=Khusch|first6=Kiran|last7=Levvey|first7=Bronwyn J.|last8=Lund|first8=Lars H.|last9=Meiser|first9=Bruno|last10=Rossano|first10=Joseph W.|last11=Stehlik|first11=Josef|title=The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time|journal=The Journal of Heart and Lung Transplantation|volume=36|issue=10|year=2017|pages=1047–1059|issn=10532498|doi=10.1016/j.healun.2017.07.016}}</ref>


===[[OKT3]]===
Even though regimens vary from center to center and case to case, most regimens consist of 2-3 drugs, usually including-  <ref>{{cite journal|doi=10.1016/j.healun.2017.07.019.}}</ref> <ref name="SöderlundRådegran2015">{{cite journal|last1=Söderlund|first1=Carl|last2=Rådegran|first2=Göran|title=Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression|journal=Transplantation Reviews|volume=29|issue=3|year=2015|pages=181–189|issn=0955470X|doi=10.1016/j.trre.2015.02.005}}</ref>


===[[Anti-thymocyte globulin]] ([[ATG]])===
===Induction Therapy===
 
* '''IL-2 Receptor antagonists'''- [[Basiliximab]] <ref name="PenningaMøller2013">{{cite journal|last1=Penninga|first1=Luit|last2=Møller|first2=Christian H|last3=Gustafsson|first3=Finn|last4=Gluud|first4=Christian|last5=Steinbrüchel|first5=Daniel A|title=Immunosuppressive T-cell antibody induction for heart transplant recipients|journal=Cochrane Database of Systematic Reviews|year=2013|issn=14651858|doi=10.1002/14651858.CD008842.pub2}}</ref>
* '''Anti-thymocyte antibodies'''- Associated with severe [[serum sickness]] like reaction <ref name="pmid18251036">{{cite journal| author=Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L | display-authors=etal| title=Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. | journal=Clin Transplant | year= 2008 | volume= 22 | issue= 1 | pages= 76-81 | pmid=18251036 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18251036  }} </ref>
 
===Maintenance Therapy===
 
*'''[[Calcineurin inhibitor]]'''- [[Tacrolimus]] or [[Cyclosporine|Cyclosporin]]; known to cause [[nephrotoxicity]], [[hypertension]], [[dyslipidemia]]. [[Gingival hyperplasia]] and [[hirsutism]] are associated with Cyclosporin alone.
*'''Anti-metabolite'''- [[Mycophenolate sodium|Mycophenolate mofetil]], [[Azathioprine]]
*''' [[Glucocorticoids]]'''- tapering dose
*''' Mammalian target of [[rapamycin]] [m-TOR] inhibitors''' and other strategies are aimed at minimizing the use of calcineurin inhibitors and corticosteroids.<ref name="HerreroMegías2016">{{cite journal|last1=Herrero|first1=María José|last2=Megías|first2=Juan Eduardo|last3=Bosó|first3=Virginia|last4=Ruiz|first4=Jesús|last5=Rojas|first5=Luis|last6=Sánchez-Lázaro|first6=Ignacio|last7=Amenar|first7=Luis|last8=Hernández|first8=Julio|last9=Poveda|first9=José Luis|last10=Pastor|first10=Amparo|last11=Solé|first11=Amparo|last12=López-Andújar|first12=Rafael|last13=Aliño|first13=Salvador F.|title=Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic|year=2016|doi=10.5772/63071}}</ref>
 
* '''Proliferation signal inhibitors ([[sirolimus]] and [[everolimus]])'''- In the case of [[cardiac allograft vasculopathy]] (CAV) or renal insufficiency
*'''Monoclonal Antibody OKT3'''- Associated with an increase in the incidence of post-transplantation [[Lymphoproliferative disorders|lymphoproliferative]] disorder<ref name="SwinnenCostanzo-Nordin1990">{{cite journal|last1=Swinnen|first1=Lode J.|last2=Costanzo-Nordin|first2=Maria R.|last3=Fisher|first3=Susan G.|last4=O'Sullivan|first4=E. Jeanne|last5=Johnson|first5=Maryl R.|last6=Heroux|first6=Alain L.|last7=Dizikes|first7=George J.|last8=Pifarre|first8=Roque|last9=Fisher|first9=Richard I.|title=Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients|journal=New England Journal of Medicine|volume=323|issue=25|year=1990|pages=1723–1728|issn=0028-4793|doi=10.1056/NEJM199012203232502}}</ref>


==References==
==References==

Latest revision as of 01:57, 8 July 2020

Heart transplantation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Complications and Prognosis

Diagnosis

Indications

Evaluation

Contraindications

Criteria for Cardiac Transplantation

Equitable Distribution of Donor Hearts to those Awaiting Transplantation and the Process of Being Listed for a Transplant

Treatment

Medical Therapy

Surgery

Follow-Up

Electrocardiogram and Pacing After Cardiac Transplantation

Heart transplantation immunosuppressive therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heart transplantation immunosuppressive therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heart transplantation immunosuppressive therapy

CDC onHeart transplantation immunosuppressive therapy

Heart transplantation immunosuppressive therapy in the news

Blogs on Heart transplantation immunosuppressive therapy

Directions to Hospitals Treating Heart transplantation

Risk calculators and risk factors for Heart transplantation immunosuppressive therapy

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D.; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1]Ifrah Fatima, M.B.B.S[2]

Overview

Post cardiac transplantation, medical therapy with immunosuppressive drugs is essential to prevent both acute and chronic rejection. Immunosuppressive therapy is given in two phases- Induction therapy and Maintenance therapy. The drugs used include different combinations of drugs like IL-2 Receptor antagonists, Anti-thymocyte antibodies, calcineurin inhibitor, anti-metabolite, glucocorticoids, mammalian target of rapamycin [m-TOR] inhibitors, proliferation signal inhibitors and monoclonal Antibody OKT3.

Medical Therapy

  • Immunosuppressive medical therapy is recommended in patients after undergoing cardiac transplantation.
  • Pharmacologic medical therapies or Post-transplantation immunosuppressive therapy includes two stages-

Even though regimens vary from center to center and case to case, most regimens consist of 2-3 drugs, usually including- [2] [3]

Induction Therapy

Maintenance Therapy

References

  1. Chambers, Daniel C.; Yusen, Roger D.; Cherikh, Wida S.; Goldfarb, Samuel B.; Kucheryavaya, Anna Y.; Khusch, Kiran; Levvey, Bronwyn J.; Lund, Lars H.; Meiser, Bruno; Rossano, Joseph W.; Stehlik, Josef (2017). "The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time". The Journal of Heart and Lung Transplantation. 36 (10): 1047–1059. doi:10.1016/j.healun.2017.07.016. ISSN 1053-2498.
  2. . doi:10.1016/j.healun.2017.07.019. Check |doi= value (help). Missing or empty |title= (help)
  3. Söderlund, Carl; Rådegran, Göran (2015). "Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression". Transplantation Reviews. 29 (3): 181–189. doi:10.1016/j.trre.2015.02.005. ISSN 0955-470X.
  4. Penninga, Luit; Møller, Christian H; Gustafsson, Finn; Gluud, Christian; Steinbrüchel, Daniel A (2013). "Immunosuppressive T-cell antibody induction for heart transplant recipients". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008842.pub2. ISSN 1465-1858.
  5. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L; et al. (2008). "Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study". Clin Transplant. 22 (1): 76–81. PMID 18251036.
  6. Herrero, María José; Megías, Juan Eduardo; Bosó, Virginia; Ruiz, Jesús; Rojas, Luis; Sánchez-Lázaro, Ignacio; Amenar, Luis; Hernández, Julio; Poveda, José Luis; Pastor, Amparo; Solé, Amparo; López-Andújar, Rafael; Aliño, Salvador F. (2016). "Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic". doi:10.5772/63071.
  7. Swinnen, Lode J.; Costanzo-Nordin, Maria R.; Fisher, Susan G.; O'Sullivan, E. Jeanne; Johnson, Maryl R.; Heroux, Alain L.; Dizikes, George J.; Pifarre, Roque; Fisher, Richard I. (1990). "Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients". New England Journal of Medicine. 323 (25): 1723–1728. doi:10.1056/NEJM199012203232502. ISSN 0028-4793.


Template:WikiDoc Sources